The formation of amyloid structures is a neuropathological feature that characterizes several neurodegenerative disorders, such as Alzheimer´s and Parkinson´s disease. Up to now, the definitive diagnostic of these diseases can only be accomplished by immunostaining of post-mortem brain tissues with dyes such as Thioflavin T and congo red. Aiming at early in vivo diagnosis of Alzheimer´s disease (AD), several amyloid-avid radioprobes have been developed for β-amyloid imaging by positron emission tomography (PET) and single-photon emitted computed tomography (SPECT). The aim of this paper is to present a perspective of the available amyloid imaging agents, special those that have been selected for clinical trials and are at the different stages of US Food and Drugs Administration (FDA) approval.